Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life

Inclusion Criteria:

- 18 years of age or older

- Diagnosis of squamous cell carcinoma of the oropharynx confirmed by the pathology
department at MSKCC

- Completed last treatment for oropharynx cancer (surgery, chemotherapy, or radiation)
at least 12 months and no more than 5 years before the date of study enrollment

- Known tumor status or tumor available for HPV testing [based on chromogenic in situ
hybridization with wide spectrum HPV probe (HPV III family 16 probe (Ventana) with
affinity to HPV genotypes 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, and 66) or p16
immunohistochemistry done in a Clinical Laboratory Improvement Amendment
(CLIA)-approved laboratory; if either of these 2 tests are positive, the patient is
classified as positive].

- Able to speak and read English (study questionnaire-Aim 1 and interview guide-Aim 2
are currently only available in English).

- Received at least one component of treatment for oropharynx cancer at MSKCC or the
regional network sites

- If radiation therapy was part of treatment, it must have been delivered at MSKCC or
the regional network sites

- For Aim 2 only, diagnosed with an HPV+ oropharynx cancer and have knowledge of this
diagnosis prior to study enrollment

Exclusion Criteria:

- Diagnosed with recurrent disease following completion of primary curative treatment